Used in research as a potent and selective inhibitor of BRAF and other kinases involved in cell signaling pathways associated with cancer. Shows activity against both wild-type and mutant BRAF, making it relevant in studies of melanoma and other solid tumors. Also demonstrates inhibitory effects on RET and TRK kinases, supporting its investigation in cancers driven by these alterations. Due to its ability to cross the blood-brain barrier, it has been explored in models of brain metastases. Primarily used in preclinical studies to evaluate targeted therapy approaches in oncology.